Results 111 to 120 of about 1,617 (165)

Impact of nirsevimab universal prophylaxis on RSV bronchiolitis hospitalizations. A tertiary level children's hospital perspective. [PDF]

Front Pediatr
Tonetto S, Cason C, Fasiolo E, Dal Cin M, Cozzi G, Giangreco M, Zappetti C, Nider S, Amaddeo A, Comar M, Travan L.   +10 more
europepmc   +1 more source

Nirsevimab in Infants: The Cost of Changing the Paradigm

Mathews Journal of Pediatrics
openaire   +1 more source

Real-world impact of nirsevimab immunisation and maternal RSV vaccination against respiratory disease on emergency department attendances and admissions: a multinational retrospective analysis. [PDF]

Lancet Reg Health Eur
Perramon-Malavez A, Chiaretti A, Coma E, Craiu M, Foster S, Leonard P, Marlow R, Thors V, Martínez-Marcos M, Mendioroz J, Vila J, Creus-Costa A, Prats C, Roland D, Soriano-Arandes A, Williams TC, Buonsenso D.   +16 more
europepmc   +1 more source

The S190R mutation in RSV-A F protein impairs nirsevimab binding and neutralization capacity. [PDF]

Virus Evol
Cordela S, Harari J, Moirangthem R, Khaleafi R, Kladnitsky O, Duran D, Grunewald M, Bar-On Y.   +7 more
europepmc   +1 more source

RSV Prevention Products and Severe RSV-Associated Disease Among Infants.

JAMA Netw Open
Bennett JC, Bevers E, Chronister S, McHugh A, Choudry M, Huynh M, Englund JA, Lindquist S, Holshue ML.   +8 more
europepmc   +1 more source

Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs. [PDF]

Front Pediatr
Love KR, Martin SE, Crowell Orella L.
europepmc   +1 more source

Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.

JAMA
Jabagi MJ, Bertrand M, Gabet A, Kolla E, Olié V, Zureik M.   +5 more
europepmc   +1 more source